Response to feedback on novel vaccines #1174
Conversation
|
AppVeyor build 1.0.5173 ... for commit 944a443 is now complete. Found 4 potential spelling error(s). Preview:content/22.vaccines-trad.md:412:gdpscattercontent/22.vaccines-trad.md:421:gdpscatter content/24.vaccines-novel.md:9:elimininating content/24.vaccines-novel.md:16:historicl The rendered manuscript from this build is temporarily available for download at: |
|
AppVeyor build 1.0.5174 for commit 91e19b5 failed. |
|
AppVeyor build 1.0.5175 for commit 9288d74 failed. |
|
AppVeyor build 1.0.5176 for commit 25ccc6b failed. |
|
AppVeyor build 1.0.5177 for commit a811662 failed. |
|
AppVeyor build 1.0.5178 for commit 1d1913e failed. |
|
AppVeyor build 1.0.5179 for commit 3d8a95b failed. |
|
AppVeyor build 1.0.5195 for commit f76a9ad is now complete. Found 0 potential spelling error(s). Preview:... |
|
I'm doing a quick round of review and will post my comments very soon |
content/24.vaccines-novel.md
Outdated
| Due to waning neutralizing antibodies and viral evolution, boosters have emerged as an important strategy in retaining the benefits of vaccination over time. | ||
| Due to waning effectiveness of vaccines over time, especially in light of viral evolution, boosters have emerged as an important strategy in retaining the benefits of vaccination over time. | ||
| Booster shots are now recommended in many places, and vaccines in the near future will likely account for multiple variants and strains of SARS-CoV-2 [@doi:10.1038/s41591-021-01230-y]. | ||
| For example, in the U.S.A., the FDA recently recommended bivalent booster doses designed to account for the Omicron VOC [@url:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-recommends-inclusion-omicron-ba45-component-covid-19-vaccine-booster; @url:https://www.medpagetoday.com/infectiousdisease/covid19vaccine/99493; @url:https://www.fda.gov/media/159597/download]. |
There was a problem hiding this comment.
| For example, in the U.S.A., the FDA recently recommended bivalent booster doses designed to account for the Omicron VOC [@url:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-recommends-inclusion-omicron-ba45-component-covid-19-vaccine-booster; @url:https://www.medpagetoday.com/infectiousdisease/covid19vaccine/99493; @url:https://www.fda.gov/media/159597/download]. | |
| For example, in the U.S.A., the FDA recently recommended bivalent booster doses designed to account for the Omicron VOC [@url:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-recommends-inclusion-omicron-ba45-component-covid-19-vaccine-booster; @url:https://www.medpagetoday.com/infectiousdisease/covid19vaccine/99493; @url:https://www.fda.gov/media/159597/download]. | |
| In this case, bivalent refers to the fact that doses deliver both the original formulation and an updated vaccine designed for the Omicron subvariants circulating in summer 2022. |
There was a problem hiding this comment.
This updated text looks good to me. However, I can't apply the suggestion because the text is now considered outdated on GitHub.
Co-authored-by: Anthony Gitter <[email protected]>
content/24.vaccines-novel.md
Outdated
| Due to waning neutralizing antibodies and viral evolution, boosters have emerged as an important strategy in retaining the benefits of vaccination over time. | ||
| Due to waning effectiveness of vaccines over time, especially in light of viral evolution, boosters have emerged as an important strategy in retaining the benefits of vaccination over time. | ||
| Booster shots are now recommended in many places, and vaccines in the near future will likely account for multiple variants and strains of SARS-CoV-2 [@doi:10.1038/s41591-021-01230-y]. | ||
| For example, in the U.S.A., the FDA recently recommended bivalent booster doses designed to account for the Omicron VOC [@url:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-recommends-inclusion-omicron-ba45-component-covid-19-vaccine-booster; @url:https://www.medpagetoday.com/infectiousdisease/covid19vaccine/99493; @url:https://www.fda.gov/media/159597/download]. |
There was a problem hiding this comment.
| For example, in the U.S.A., the FDA recently recommended bivalent booster doses designed to account for the Omicron VOC [@url:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-recommends-inclusion-omicron-ba45-component-covid-19-vaccine-booster; @url:https://www.medpagetoday.com/infectiousdisease/covid19vaccine/99493; @url:https://www.fda.gov/media/159597/download]. | |
| For example, in the U.S.A., the FDA recently recommended bivalent booster doses designed to account for the Omicron VOC [@url:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-recommends-inclusion-omicron-ba45-component-covid-19-vaccine-booster; @url:https://www.medpagetoday.com/infectiousdisease/covid19vaccine/99493; @url:https://www.fda.gov/media/159597/download]. | |
| In this case, bivalent refers to the fact that doses deliver both the original formulation and an updated vaccine designed for the Omicron subvariants circulating in summer 2022. |
Co-authored-by: HM Rando <[email protected]>
|
AppVeyor build 1.0.5200 for commit 31af994 is now complete.... Found 0 potential spelling error(s). Preview:The rendered manuscript from this build is temporarily available for download at: |
The standard identifiers override the id
|
AppVeyor build 1.0.5203 |
|
Appveyor failed, so not sure what's that's about, but I'm not seeing error messages about the references anymore in the manubot build, so I think I might have done the manual references correctly! |
There was a problem hiding this comment.
I updated the manual references in ebb6f64 to remove the note field. Manubot includes a standard identifier in the note, which overrides the id if both are present.
I checked the GitHub HTML artifact and build logs quickly and they look good. These two small issues are the only ones I found.
Before merging, we can also update 90.back-matter.md to use the new arXiv reference for @individual-vaccines-traditional and delete it from manual-references.json. I can push that change directly if you'd like.
Co-authored-by: Anthony Gitter <[email protected]>
Co-authored-by: Anthony Gitter <[email protected]>
|
Thanks @agitter! I just updated the back matter, manual references, and the read me as well |
|
AppVeyor build 1.0.5206 for commit e6601ff is now complete. Found 0 potential spelling error(s). Preview:... |
[ci skip] This build is based on b48f98d. This commit was created by the following CI build and job: https://github.com/greenelab/covid19-review/commit/b48f98d4a6a1007343ac196cd06f9a2f3af6f821/checks https://github.com/greenelab/covid19-review/actions/runs/2988849418
[ci skip] This build is based on b48f98d. This commit was created by the following CI build and job: https://github.com/greenelab/covid19-review/commit/b48f98d4a6a1007343ac196cd06f9a2f3af6f821/checks https://github.com/greenelab/covid19-review/actions/runs/2988849418
|
The GitHub Pages deployment failed. I don't understand why this timed out. The content was pushed to the Edit: tracking in #1177 |
Description of the proposed additions or changes
Here are my responses to feedback from @RLordan and @agitter. When this merges, we may be ready to preprint (I need to run the final word version by one collaborator who is not on GitHub).
Related issues
Suggested reviewers (optional)
Checklist